T de La Motte Rouge1, P Pautier1, P Duvillard2, A Rey3, P Morice4, C Haie-Meder5, P Kerbrat6, S Culine7, F Troalen2, C Lhommé8. 1. Department of Medical Oncology, Institut Gustave Roussy, Villejuif. 2. Department of Biopathology, Institut Gustave Roussy, Villejuif. 3. Department of Biostatistics, Institut Gustave Roussy, Villejuif. 4. Department of Surgery, Institut Gustave Roussy, Villejuif. 5. Department of Radiotherapy, Institut Gustave Roussy, Villejuif. 6. Centre Eugène Marquis, Université de Rennes 1, Rennes. 7. Centre Régional de Lutte Contre le Cancer Val d'Aurelle, Montpellier, France. 8. Department of Medical Oncology, Institut Gustave Roussy, Villejuif. Electronic address: lhomme@igr.fr.
Abstract
BACKGROUND: Ovarian yolk sac tumor (YST) is a very rare malignancy arising in young women. Chemotherapy has dramatically improved the prognosis. Current treatment consists of surgery followed by bleomycin, etoposide, and cisplatin (BEP) chemotherapy. However, given the rarity of this tumor, ovarian YST-specific survival and outcome after such treatment are not precisely known. PATIENTS AND METHODS: This report concerns prospectively recorded cases that were either treated at Institut Gustave Roussy (Villejuif, France) or referred there for advice about therapy. From 1990 to 2006, 52 patients underwent surgery followed by BEP chemotherapy. Data on patient characteristics, treatment, survival, and fertility outcome were analyzed to assess treatment efficacy and gonadal toxicity after achieving a complete remission. RESULTS: Thirty-five patients had stage I/II tumors while 17 patients presented with stage III/IV disease. With a median follow-up of 68 months, the overall 5-year survival and disease-free survival rates were 94% and 90%, respectively. Forty-one women underwent fertility-sparing surgery. Pregnancy was achieved in 12 of 16 (75%) women who attempted conception. Overall, 19 pregnancies have been recorded. CONCLUSIONS: BEP chemotherapy following fertility-sparing surgery is a very effective treatment of ovarian YSTs. Most of the patients who attempt conception after complete remission will have children.
BACKGROUND:Ovarian yolk sac tumor (YST) is a very rare malignancy arising in young women. Chemotherapy has dramatically improved the prognosis. Current treatment consists of surgery followed by bleomycin, etoposide, and cisplatin (BEP) chemotherapy. However, given the rarity of this tumor, ovarian YST-specific survival and outcome after such treatment are not precisely known. PATIENTS AND METHODS: This report concerns prospectively recorded cases that were either treated at Institut Gustave Roussy (Villejuif, France) or referred there for advice about therapy. From 1990 to 2006, 52 patients underwent surgery followed by BEP chemotherapy. Data on patient characteristics, treatment, survival, and fertility outcome were analyzed to assess treatment efficacy and gonadal toxicity after achieving a complete remission. RESULTS: Thirty-five patients had stage I/II tumors while 17 patients presented with stage III/IV disease. With a median follow-up of 68 months, the overall 5-year survival and disease-free survival rates were 94% and 90%, respectively. Forty-one women underwent fertility-sparing surgery. Pregnancy was achieved in 12 of 16 (75%) women who attempted conception. Overall, 19 pregnancies have been recorded. CONCLUSIONS:BEP chemotherapy following fertility-sparing surgery is a very effective treatment of ovarian YSTs. Most of the patients who attempt conception after complete remission will have children.
Authors: Brigitte Gerstl; Elizabeth Sullivan; Marcus Vallejo; Jana Koch; Maximilian Johnson; Handan Wand; Kate Webber; Angela Ives; Antoinette Anazodo Journal: J Cancer Surviv Date: 2019-04-17 Impact factor: 4.442
Authors: Wing Ho Mui; Ka Chai Lee; Sin Chuen Chiu; Chun Yin Pang; Sau Kwan Chu; Chi Wai Man; Chi Sing Wong; Wing Kin Sze; Yuk Tung Journal: Oncol Lett Date: 2013-11-08 Impact factor: 2.967